Advanced search
Publication Cover
Journal of Hepatocellular Carcinoma Volume 11, 2024 - Issue
Submit an article Journal homepage
86
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma

Shadi Chamseddine1 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Michael LaPelusa2 Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Lianchun Xiao3 Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Yehia I Mohamed1 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-5192-3804View further author information
ORCID Icon,
Sunyoung S Lee1 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Zishuo Ian Hu1 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
Rikita I Hatia4 Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0003-2591-5963View further author information
ORCID Icon,
Manal Hassan4 Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAView further author information
,
James C Yao1 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0002-1875-3962View further author information
ORCID Icon,
Dan G Duda5 Steele Laboratories, Department of Radiation Oncology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USAView further author information
,
Saumil Datar6 Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX, USAView further author information
,
Hesham M Amin7 Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;8 MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-7973-6699View further author information
ORCID Icon &
Ahmed O Kaseb1 Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
View further author information
 show all
Pages 455-461 | Received 13 Dec 2023, Accepted 28 Feb 2024, Published online: 04 Mar 2024

References

  • Asafo-Agyei KO, Samant H. Hepatocellular Carcinoma. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.
  • Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clinicians. 2021;71(3):209–249. doi:10.3322/caac.21660
  • Philips CA, Rajesh S, Nair DC, et al. Hepatocellular carcinoma in 2021: an exhaustive update. Cureus. 2021;13(11):e19274. doi:10.7759/cureus.19274
  • Crissien AM, Frenette C. Current management of hepatocellular carcinoma. Gastroenterol Hepatol. 2014;10(3):153–161.
  • Chen Z, Xie H, Hu M, et al. Recent progress in treatment of hepatocellular carcinoma. Am J Cancer Res. 2020;10(9):2993–3036.
  • Dipasquale A, Marinello A, Santoro A. A comparison of lenvatinib versus sorafenib in the first-line treatment of unresectable hepatocellular carcinoma: selection criteria to guide physician’s choice in a new therapeutic scenario. J Hepatocell Carcinoma. 2021;8:241–251. doi:10.2147/JHC.S270532
  • Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905. doi:10.1056/NEJMoa1915745
  • Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence. 2022;1(8):EVIDoa2100070. doi:10.1056/EVIDoa2100070
  • Kudo M. Durvalumab plus tremelimumab in unresectable hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2022;11(4):592–596. doi:10.21037/hbsn-22-143
  • Chen Y-J, You M-L, Chong Q-Y, et al. Autocrine human growth hormone promotes invasive and cancer stem cell-like behavior of hepatocellular carcinoma cells by STAT3 dependent inhibition of CLAUDIN-1 expression. Int J Mol Sci. 2017;18(6):1274. doi:10.3390/ijms18061274
  • Boguszewski CL, Boguszewski M. Growth hormone’s links to cancer. Endocr Rev. 2019;40(2):558–574. doi:10.1210/er.2018-00166
  • Snibson KJ, Bhathal PS, Adams TE. Overexpressed growth hormone (GH) synergistically promotes carcinogen-initiated liver tumour growth by promoting cellular proliferation in emerging hepatocellular neoplasms in female and male GH-transgenic mice. Liver. 2001;21(2):149–158. doi:10.1034/j.1600-0676.2001.021002149.x
  • Kaseb AO, Haque A, Vishwamitra D, et al. Blockade of growth hormone receptor signaling by using pegvisomant: a functional therapeutic strategy in hepatocellular carcinoma. Front Oncol. 2022;12:986305. doi:10.3389/fonc.2022.986305
  • Haque A, Sahu V, Lombardo JL, et al. Disruption of growth hormone receptor signaling abrogates hepatocellular carcinoma development. J Hepatocell Carcinoma. 2022;9:823–837. doi:10.2147/JHC.S368208
  • Abdel-Wahab R, Shehata S, Hassan MM, et al. Type I insulin-like growth factor as a liver reserve assessment tool in hepatocellular carcinoma. J Hepatocell Carcinoma. 2015;2:131–142. doi:10.2147/JHC.S81309
  • Morris JS, Hassan MM, Zohner YE, et al. HepatoScore-14: measures of biological heterogeneity significantly improve prediction of hepatocellular carcinoma risk. Hepatology. 2021;73(6):2278–2292. doi:10.1002/hep.31555
  • Mohamed YI, Duda DG, Awiwi MO, et al. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 2022;13:1314–1321. doi:10.18632/oncotarget.28322

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.